Lazanda

Lazanda is a brand name of fentanyl, approved by the FDA in the following formulation(s):

LAZANDA (fentanyl citrate - spray, metered; nasal)

• 
  Manufacturer: ARCHIMEDES
  
  Approval date: June 30, 2011
  
  Strength(s): EQ 0.1MG BASE, EQ 0.4MG BASE ^[RLD]

Has a generic version of Lazanda been approved?

No. There is currently no therapeutically equivalent version of Lazanda available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lazanda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces
  Patent 6,432,440
  Issued: August 13, 2002
  Inventor(s): Peter James; Watts & Lisbeth; Illum
  Assignee(s): West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited
  Liquid pharmaceutical compositions for administration to a mucosal surface, comprising a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.
  
  Patent expiration dates:
  
  
  • April 20, 2018
    
    ✓ 
    Patent use: MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 30, 2014 - NEW DOSAGE FORM
  
  

See also...

• Lazanda Consumer Information (Drugs.com)
• Lazanda Spray Consumer Information (Wolters Kluwer)
• Lazanda nasal Consumer Information (Cerner Multum)
• Fentanyl Consumer Information (Drugs.com)
• Fentanyl Consumer Information (Wolters Kluwer)
• Fentanyl Lozenge Consumer Information (Wolters Kluwer)
• Fentanyl Patch Consumer Information (Wolters Kluwer)
• Fentanyl Soluble Film Consumer Information (Wolters Kluwer)
• Fentanyl Spray Consumer Information (Wolters Kluwer)
• Fentanyl Tablet Consumer Information (Wolters Kluwer)
• Fentanyl buccal Consumer Information (Cerner Multum)
• Fentanyl citrate oral transmucosal Consumer Information (Cerner Multum)
• Fentanyl nasal Consumer Information (Cerner Multum)
• Fentanyl sublingual Consumer Information (Cerner Multum)
• Fentanyl transdermal device Consumer Information (Cerner Multum)
• Fentanyl transdermal skin patch Consumer Information (Cerner Multum)
• Fentanyl Buccal mucosa, Oromucosal Advanced Consumer Information (Micromedex)
• Fentanyl Nasal Advanced Consumer Information (Micromedex)
• Fentanyl Transdermal Advanced Consumer Information (Micromedex)
• Fentanyl Citrate AHFS DI Monographs (ASHP)